5PSQ-056 Vaccination coverage against penumococcus for people living with HIV before and after the COVID-19 pandemic

• Published in: European journal of hospital pharmacy. Science and practice 2024-03, Vol.31 (Suppl 1), p.A189-A189
• Main Authors: Vélez-Díaz-Pallarés, M, Fernández Chávez, AC, Guijarro Martínez, P, Aranaz-Andrés, JM, Álvarez Díaz, AM
• Format: Article
• Language: English
• Subjects: Conflicts of interest; COVID-19 vaccines; HIV; Human immunodeficiency virus; Immunization; Pandemics; Section 5: Patient safety and quality assurance
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2024-eahp.390

Background and ImportanceImmunisation is the best prevention against pneumococcal diseases in people living with HIV (PLHIV). From 2010 to 2022, the recommended vaccination schedule was sequential: 13v conjugate vaccine followed by the 23v polysaccharide vaccine.Aim and ObjectivesThe aim of the study was to describe and compare vaccine coverage against pneumococcus before and after the COVID-19 pandemic in (PLHIV).Material and MethodsThe sample was obtained from patients who attended the Pharmacy Department of a tertiary hospital in the years 2019 and 2022 to receive their antiretroviral drugs. Vaccination data were obtained from the SISPAL database of the Community of Madrid. Vaccination coverage between 2019 and 2022 was estimated and compared using bivariate logistic regression.ResultsIn total, PLHIV were 2,978 and 3,169 in 2019 and 2022 respectively. The median age was 47 (37–53) and 46 (35–53) respectively. Men were more prevalent, with 81.5% in 2019 and 81.9% in 2022. 62.7% and 68.5% received the sequential anti-pneumococcal regimen in 2019 and 2022, respectively (OR 1.29 95%; CI: 1.13–1.48; p